Sympathoadrenergic modulation of hematopoiesis: a review of available evidence and of therapeutic perspectives.
Sympathoadrenergic modulation of hematopoiesis: a review of available evidence and of therapeutic perspectives.
复制标题
DOI：
10.3389/fncel.2015.00302
复制
发表时间：
2015
影响因子：
5.3
通讯作者：
Maestroni GJ
中科院分区：
文献类型：
--
作者：
Cosentino M;Marino F;Maestroni GJ
骨髓(BM)的神经支配早在一个多世纪前就已被描述，然而，交感肾上腺素能纤维在造血中发挥作用的第一个活体证据可以追溯到不到25年前。自那以后，越来越多的证据表明，骨髓中的肾上腺素能神经释放去甲肾上腺素，可能还有多巴胺，作用于造血细胞上表达的肾上腺素受体和多巴胺受体(DR)，影响细胞的存活、增殖、迁移和植入能力。值得注意的是，肾上腺素能纤维对骨髓的调节失调与造血障碍和骨髓增生性疾病有关。几种肾上腺素能和多巴胺能药已经在临床上用于非血液学适应症，并且通常具有良好的风险-效益曲线，因此是非传统造血调控的潜在候选者。
Innervation of the bone marrow (BM) has been described more than one century ago, however the first in vivo evidence that sympathoadrenergic fibers have a role in hematopoiesis dates back to less than 25 years ago. Evidence has since increased showing that adrenergic nerves in the BM release noradrenaline and possibly also dopamine, which act on adrenoceptors and dopaminergic receptors (DR) expressed on hematopoietic cells and affect cell survival, proliferation, migration and engraftment ability. Remarkably, dysregulation of adrenergic fibers to the BM is associated with hematopoietic disturbances and myeloproliferative disease. Several adrenergic and dopaminergic agents are already in clinical use for non-hematological indications and with a usually favorable risk-benefit profile, and are therefore potential candidates for non-conventional modulation of hematopoiesis.